Stimulated γδ T cells increase the in vivo efficacy of trastuzumab in HER-2+ breast cancer

Journal of Immunology

Volumn 187, Issue 2, 2011, Pages 1031-1038

  Capietto, Aude Hélène ^a,b,e   Martinet, Ludovic ^b,c   Fournié, Jean Jacques ^a,b,d  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^d CHU PURPAN   (France)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; OPSONIZATION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GROWTH INHIBITORS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, SCID; PHOSPHOPROTEINS; RECEPTOR, ERBB-2; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION, HETEROLOGOUS;

EID: 79960543670     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1100681     Document Type: Article

References (71)

1. Slamon, D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
2. Carter, P., L. Presta, C. M. Gorman, J. B. Ridgway, D. Henner, W. L. Wong, A. M. Rowland, C. Kotts, M. E. Carver, and H. M. Shepard. 1992. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 89: 4285-4289.
3. Baselga, J., L. Norton, J. Albanell, Y. M. Kim, and J. Mendelsohn. 1998. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58: 2825-2831.
4. Vogel,C. L., M. A. Cobleigh, D. Tripathy, J. C. Gutheil, L. N. Harris, L. Fehrenbacher, D. J. Slamon, M. Murphy, W. F. Novotny, M. Burchmore, et al. 2001. First-line Herceptin monotherapy in metastatic breast cancer. Oncology 61(Suppl 2): 37-42. (Pubitemid 33033423)
5. Osoba, D., and M. Burchmore. 1999. Health-related quality of life in women with metastatic breast cancer treated with trastuzumab (Herceptin). Semin. Oncol. 26(4, Suppl 12): 84-88. (Pubitemid 29411437)
6. Nahta, R., and F. J. Esteva. 2007. Trastuzumab: triumphs and tribulations. Oncogene 26: 3637-3643.
7. Drebin, J. A., V. C. Link, D. F. Stern, R. A. Weinberg, and M. I. Greene. 1985. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41: 697-706.
8. Lane, H. A., I. Beuvink, A. B. Motoyama, J. M. Daly, R. M. Neve, and N. E. Hynes. 2000. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol. Cell. Biol. 20: 3210-3223.
9. Klapper, L. N., N. Vaisman, E. Hurwitz, R. Pinkas-Kramarski, Y. Yarden, and M. Sela. 1997. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/ HER2 blocks crosstalk with growth factor receptors. Oncogene 14: 2099-2109. (Pubitemid 27237013)
10. Izumi, Y., L. Xu, E. di Tomaso, D. Fukumura, and R. K. Jain. 2002. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416: 279-280.
11. Sliwkowski, M. X., J. A. Lofgren, G. D. Lewis, T. E. Hotaling, B. M. Fendly, and J. A. Fox. 1999. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. 26(4, Suppl 12): 60-70.
12. Cooley, S., L. J. Burns, T. Repka, and J. S. Miller. 1999. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp. Hematol. 27: 1533-1541.
13. Gennari, R., S. Menard, F. Fagnoni, L. Ponchio, M. Scelsi, E. Tagliabue, F. Castiglioni, L. Villani, C. Magalotti, N. Gibelli, et al. 2004. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin. Cancer Res. 10: 5650-5655.
14. Kute, T. E., L. Savage, J. R. Stehle, Jr., J. W. Kim-Shapiro, M. J. Blanks, J. Wood, and J. P. Vaughn. 2009. Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing. Cancer Immunol. Immunother. 58: 1887-1896.
15. Varchetta, S., N. Gibelli, B. Oliviero, E. Nardini, R. Gennari, G. Gatti, L. S. Silva, L. Villani, E. Tagliabue, S. Ménard, et al. 2007. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res. 67: 11991-11999.
16. Pupa, S. M., R. Bufalino, A. M. Invernizzi, S. Andreola, F. Rilke, L. Lombardi, M. I. Colnaghi, and S. Ménard. 1996. Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas. J. Clin. Oncol. 14: 85-94.
17. Geyer, C. E., J. Forster, D. Lindquist, S. Chan, C. G. Romieu, T. Pienkowski, A. Jagiello-Gruszfeld, J. Crown, A. Chan, B. Kaufman, et al. 2006. Lapatinib plus capecitabine for HER2-positive advanced breast cancer.N. Engl. J. Med. 355: 2733-2743.
18. Spector, N. L., and K. L. Blackwell. 2009. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 27: 5838-5847.
19. Poupot, M., and J. J. Fournié. 2004. Non-peptide antigens activating human Vgamma9/Vdelta2 T lymphocytes. Immunol. Lett. 95: 129-138.
20. Belmant, C., D. Decise, and J. J. Fournie. 2006. Phosphoantigens and aminobisphosphonates: new leads targeting gamma delta T lymphocytes for cancer immunotherapy. Drug Discov. Today Ther. Strateg. 3: 17-23.
21. Angelini, D. F., G. Borsellino, M. Poupot, A. Diamantini, R. Poupot, G. Bernardi, F. Poccia, J. J. Fournié, and L. Battistini. 2004. FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways. Blood 104: 1801-1807. (Pubitemid 39202290)
22. Caccamo, N., L. Battistini, M. Bonneville, F. Poccia, J. J. Fournié, S. Meraviglia, G. Borsellino, R. A. Kroczek, C. La Mendola, E. Scotet, et al. 2006. CXCR5 identifies a subset of Vgamma9Vdelta2 T cells which secrete IL-4 and IL-10 and help B cells for antibody production. J. Immunol. 177: 5290-5295. (Pubitemid 44527601)
23. Rincon-Orozco, B., V. Kunzmann, P. Wrobel, D. Kabelitz, A. Steinle, and T. Herrmann. 2005. Activation of V gamma 9V delta 2 T cells by NKG2D. J. Immunol. 175: 2144-2151. (Pubitemid 41113819)
24. Lafont, V., J. Liautard, J. P. Liautard, and J. Favero. 2001. Production of TNF-alpha by human V gamma 9V delta 2 T cells via engagement of Fc gamma RIIIA, the low affinity type 3 receptor for the Fc portion of IgG, expressed upon TCR activation by nonpeptidic antigen. J. Immunol. 166: 7190-7199. (Pubitemid 32525592)
25. Gertner-Dardenne, J., C. Bonnafous, C. Bezombes, A. H. Capietto, V. Scaglione, S. Ingoure, D. Cendron, E. Gross, J. F. Lepage, A. Quillet-Mary, et al. 2009. Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood 113: 4875-4884.
26. Espinosa, E., C. Belmant, F. Pont, B. Luciani, R. Poupot, F. Romagné, H. Brailly, M. Bonneville, and J. J. Fournié. 2001. Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human gamma delta T cells. J. Biol. Chem. 276: 18337-18344.
27. Song, Y., Y. Zhang, H.Wang, A. M. Raker, J. M. Sanders, E. Broderick, A. Clark, C. T. Morita, and E. Oldfield. 2004. Synthesis of chiral phosphoantigens and their activity ingamma deltaTcell stimulation. Bioorg.Med.Chem.Lett. 14:4471-4477. (Pubitemid 39055972)
28. Boëdec, A., H. Sicard, J. Dessolin, G. Herbette, S. Ingoure, C. Raymond, C. Belmant, and J. L. Kraus. 2008. Synthesis and biological activity of phosphonate analogues and geometric isomers of the highly potent phosphoantigen (E)-1-hydroxy-2-methylbut-2-enyl 4-diphosphate. J. Med. Chem. 51: 1747-1754.
29. Breccia, P., F. Angeli, I. Cerbara, A. Topai, G. Auricchio, A. Martino, V. Colizzi, and F. Poccia. 2009. Thiopyrophosphoantigens: solid-phase synthesis and in vitro characterization of a new class of Vgamma9 Vdelta2 T cells activators. J. Med. Chem. 52: 3716-3722.
30. Kunzmann, V., E. Bauer, and M. Wilhelm. 1999. Gamma/delta T-cell stimulation by pamidronate. N. Engl. J. Med. 340: 737-738.
31. Gober, H. J., M. Kistowska, L. Angman, P. Jenö, L. Mori, and G. De Libero. 2003. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 197: 163-168.
32. Thompson, K., and M. J. Rogers. 2004. Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro. J. Bone Miner. Res. 19: 278-288.
33. Casetti, R., G. Perretta, A. Taglioni, M. Mattei, V. Colizzi, F. Dieli, G. D'Offizi, M. Malkovsky, and F. Poccia. 2005. Drug-induced expansion and differentiation of V gamma9Vdelta2Tcellsinvivo:theroleofexogenousIL-2.J. Immunol.175:1593-1598.
34. Sicard, H., S. Ingoure, B. Luciani, C. Serraz, J. J. Fournié, M. Bonneville, J. Tiollier, and F. Romagné. 2005. In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J. Immunol. 175: 5471-5480.
35. Wilhelm, M., V. Kunzmann, S. Eckstein, P. Reimer, F. Weissinger, T. Ruediger, and H. P. Tony. 2003. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 102: 200-206.
36. Dieli, F., D. Vermijlen, F. Fulfaro, N. Caccamo, S. Meraviglia, G. Cicero, A. Roberts, S. Buccheri, M. D'Asaro, N. Gebbia, et al. 2007. Targeting human gammadelta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 67: 7450-7457. (Pubitemid 47206575)
37. Bennouna, J., E. Bompas, E. M. Neidhardt, F. Rolland, I. Philip, C. Galéa, S. Salot, S. Saiagh, M. Audrain, M. Rimbert, et al. 2008. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol. Immunother. 57: 1599-1609.
38. Kobayashi, H., Y. Tanaka, J. Yagi, Y. Osaka, H. Nakazawa, T. Uchiyama, N. Minato, and H. Toma. 2007. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol. Immunother. 56: 469-476.
39. Kunzmann, V., and M. Wilhelm. 2005. Anti-lymphoma effect of gammadelta T cells. Leuk. Lymphoma 46: 671-680.
40. Bonneville, M., and E. Scotet. 2006. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr. Opin. Immunol. 18: 539-546.
41. Kabelitz, D., D. Wesch, and W. He. 2007. Perspectives of gammadelta T cells in tumor immunology. Cancer Res. 67: 5-8. (Pubitemid 46142752)
42. Dieli, F., N. Caccamo, and S. Meraviglia. 2008. Advances in immunotherapy of castration-resistant prostate cancer: bisphosphonates, phosphoantigens and more. Curr. Opin. Investig. Drugs 9: 1089-1094.
43. Tokuyama, H., T. Hagi, S. R. Mattarollo, J. Morley, Q. Wang, H. Fai-So, F. Moriyasu, M. Nieda, and A. J. Nicol. 2008. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs - rituximab and trastuzumab. Int. J. Cancer 122: 2526-2534.
44. Kondo, M., K. Sakuta, A. Noguchi, N. Ariyoshi, K. Sato, S. Sato, K. Sato, A. Hosoi, J. Nakajima, Y. Yoshida, et al. 2008. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 10: 842-856.
45. Braza, M. S., A. Caraux, T. Rousset, S. Lafaye de Micheaux, H. Sicard, P. Squiban, V. Costes, B. Klein, and J. F. Rossi. 2010. gammadelta T lymphocytes count is normal and expandable in peripheral blood of patients with follicular lymphoma, whereas it is decreased in tumor lymph nodes compared with inflammatory lymph nodes. J. Immunol. 184: 134-140.
46. Kunzmann, V., B. Kimmel, T. Herrmann, H. Einsele, and M. Wilhelm. 2009. Inhibition of phosphoantigen-mediated gammadelta T-cell proliferation by CD4 + CD25+ FoxP3+ regulatory T cells. Immunology 126: 256-267.
47. Fisch, P., G. Weil-Hillman, M. Uppenkamp, J. A. Hank, B. P. Chen, J. A. Sosman, A. Bridges, O. R. Colamonici, and P. M. Sondel. 1989. Antigen-specific recognition of autologous leukemia cells and allogeneic class-I MHC antigens by IL-2-activated cytotoxic T cells from a patient with acute T-cell leukemia. Blood 74: 343-353.
48. Koide, J., A. Rivas, and E. G. Engleman. 1989. Natural killer (NK)-like cytotoxic activity of allospecific T cell receptor-gamma,delta+ T cell clones. Distinct receptor-ligand interactions mediate NK-like and allospecific cytotoxicity. J. Immunol. 142: 4161-4168.
49. Kabelitz, D., A. Bender, S. Schondelmaier, M. L. da Silva Lobo, and O. Janssen. 1990. Human cytotoxic lymphocytes. V. Frequency and specificity of gamma delta+ cytotoxic lymphocyte precursors activated by allogeneic or autologous stimulator cells. J. Immunol. 145: 2827-2832.
50. Burstein, H. J., L. N. Harris, R. Gelman, S. C. Lester, R. A. Nunes, C. M. Kaelin, L. M. Parker, L. W. Ellisen, I. Kuter, M. A. Gadd, et al. 2003. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J. Clin. Oncol. 21: 46-53.
51. Kute, T., C. M. Lack, M. Willingham, B. Bishwokama, H. Williams, K. Barrett, T. Mitchell, and J. P. Vaughn. 2004. Development of Herceptin resistance in breast cancer cells. Cytometry A 57: 86-93.
52. Capietto, A. H., S. Keirallah, E. Gross, N. Dauguet, E. Laprévotte, C. Jean, J. Gertner-Dardenne, C. Bezombes, A. Quillet-Mary, M. Poupot, et al. 2010. Emerging concepts for the treatment of hematological malignancies with therapeutic monoclonal antibodies. Curr. Drug Targets 11: 790-800.
53. Dewan, M. Z., M. Takada, H. Terunuma, X. Deng, S. Ahmed, N. Yamamoto, and M. Toi. 2009. Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients. Biomed. Pharmacother. 63: 703-706.
54. Fleming, G. F., N. J. Meropol, G. L. Rosner, D. R. Hollis, W. E. Carson, III, M. Caligiuri, J. Mortimer, K. Tkaczuk, R. Parihar, R. L. Schilsky, and M. J. Ratain. 2002. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin. Cancer Res. 8: 3718-3727.
55. Parihar, R., P. Nadella, A. Lewis, R. Jensen, C. De Hoff, J. E. Dierksheide, A. M. VanBuskirk, C. M. Magro, D. C. Young, C. L. Shapiro, and W. E. Carson III,. 2004. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. Clin. Cancer Res. 10: 5027-5037.
56. Dieli, F., F. Poccia, M. Lipp, G. Sireci, N. Caccamo, C. Di Sano, and A. Salerno. 2003. Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J. Exp. Med. 198: 391-397.
57. Alam, S. M., J. S. Clark, V. Leech, P. Whitford, W. D. George, and A. M. Campbell. 1992. T cell receptor gamma/delta expression on lymphocyte populations of breast cancer patients. Immunol. Lett. 31: 279-283.
58. Malkovska, V., F. K. Cigel, N. Armstrong, B. E. Storer, and R. Hong. 1992. Antilymphoma activity of human gamma delta T-cells in mice with severe combined immune deficiency. Cancer Res. 52: 5610-5616.
59. Zheng, B. J., K. W. Chan, S. Im, D. Chua, J. S. Sham, P. C. Tin, Z. M. He, and M. H. Ng. 2001. Anti-tumor effects of human peripheral gammadelta T cells in a mouse tumor model. Int. J. Cancer 92: 421-425.
60. Lozupone, F., D. Pende, V. L. Burgio, C. Castelli, M. Spada, M. Venditti, F. Luciani, L. Lugini, C. Federici, C. Ramoni, et al. 2004. Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice. Cancer Res. 64: 378-385.
61. DeNardo, D. G., and L. M. Coussens. 2007. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 9: 212.
62. Ruffell, B., D. G. DeNardo, N. I. Affara, and L. M. Coussens. 2010. Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev. 21: 3-10.
63. Musolino, A., N. Naldi, B. Bortesi, D. Pezzuolo, M. Capelletti, G. Missale, D. Laccabue, A. Zerbini, R. Camisa, G. Bisagni, et al. 2008. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 26: 1789-1796.
64. Meraviglia, S., M. Eberl, D. Vermijlen, M. Todaro, S. Buccheri, G. Cicero, C. La Mendola, G. Guggino, M. D'Asaro, V. Orlando, et al. 2010. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin. Exp. Immunol. 161: 290-297.
65. Meraviglia, S., N. Caccamo, G. Guggino, M. Tolomeo, S. Siragusa, G. Stassi, and F. Dieli. 2010. Optimizing tumor-reactive gd T cells for antibody-based cancer immunotherapy. Curr. Mol. Med. 10: 719-726.
66. Capietto, A. H., L. Martinet, D. Cendron, S. Fruchon, F. Pont, and J. J. Fournié. 2010. Phosphoantigens overcome human TCRVgamma9+ gammadelta Cell immunosuppression by TGF-beta: relevance for cancer immunotherapy. J. Immunol. 184: 6680-6687.
67. Desruisseau, S., J. Palmari, C. Giusti, S. Romain, P. M. Martin, and Y. Berthois. 2006. Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival. Br. J. Cancer 94: 239-246. (Pubitemid 43151542)
68. Ivanović, V., M. Demajo, K. Krtolica, M. Krajnović, M. Konstantinović, V. Baltić, G. Prtenjak, B. Stojiljković, M. Breberina, Z. Nesković-Konstantinović, et al. 2006. Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients. Clin. Chim. Acta 371: 191-193.
69. Soslow, R. A., A. J. Dannenberg, D. Rush, B. M. Woerner, K. N. Khan, J. Masferrer, and A. T. Koki. 2000. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89: 2637-2645.
70. Watson, J., and S. Y. Chuah. 1985. Prostaglandins, steroids and human mammary cancer. Eur. J. Cancer Clin. Oncol. 21: 1051-1055.
71. Martinet, L., C. Jean, G. Dietrich, J. J. Fournie, and R. Poupot. 2010. PGE2 inhibits natural killer and gamma delta T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling. Biochem. Pharmacol. 80: 838-845.